Can a blood test or a sample of fluid around the lungs establish whether someone has mesothelioma? A new study offers a reason for caution about one proposed cancer marker.
Researchers at Cairo University examined tumor M2-pyruvate kinase (TuM2-PK) in patients with malignant and nonmalignant pleural effusions. Their study, published November 18, 2026, in The Egyptian Journal of Bronchology, found that the marker did not reliably distinguish the groups.
This research does not establish a new mesothelioma test. Instead, it reinforces why laboratory findings must be interpreted alongside imaging, clinical evaluation and, when appropriate, tissue pathology.
Why does pleural fluid matter in mesothelioma diagnosis?
Pleural mesothelioma develops in the lining around the lungs. Some patients develop a pleural effusion—fluid between the lung and chest wall—which may cause breathlessness or discomfort. Doctors can sample the fluid to investigate its cause and, in some cases, remove fluid to ease symptoms.
Fluid may accumulate for many reasons, including infection, inflammation, heart conditions and cancer. A pleural effusion alone does not establish mesothelioma. A negative fluid test also may not settle the diagnosis if imaging or other findings remain concerning.
What did the researchers investigate?
Researchers at Cairo University studied tumor M2-pyruvate kinase (TuM2-PK), a protein associated with cellular metabolism that has been investigated as a potential cancer marker. They analyzed blood and pleural fluid samples from 88 patients: 44 with malignant pleural effusions and 44 with nonmalignant exudative effusions. Of the 44 malignant cases, 26 involved mesothelioma. The other cases involved different cancers.
The researchers asked whether TuM2-PK levels in serum or pleural fluid could distinguish the two groups.
What did the blood test show?
At the selected serum threshold, TuM2-PK had 63.6% sensitivity and 52.3% specificity for distinguishing malignant from nonmalignant pleural effusions. Sensitivity is the proportion of affected patients a test identifies; specificity is the proportion of unaffected patients it correctly identifies. Insufficient sensitivity can miss disease, while poor specificity can produce positive findings in people without it.
Serum levels were higher in the malignant group in an initial comparison, but the malignant group was also older on average. After adjusting for other factors, serum TuM2-PK was no longer significantly associated with malignancy. Pleural-fluid measurements and the fluid-to-serum ratio also did not provide reliable diagnostic separation.
These performance figures concern malignant effusions generally. They are not validated accuracy figures for diagnosing mesothelioma specifically.
Why is a biopsy sometimes necessary?
Mesothelioma can resemble other cancers and noncancerous changes in the pleura. Imaging and fluid cytology can provide useful information, but tissue examination and specialized pathology tests are often needed to establish a confident diagnosis. The National Cancer Institute describes biopsy, thoracoscopy, cytology and immunohistochemistry among the procedures used in evaluating mesothelioma.
This study did not demonstrate that TuM2-PK can replace established diagnostic evaluation. For more context, see our guide to mesothelioma diagnosis.
How is this different from BAP1 testing?
Our earlier BAP1 diagnostic-testing report concerned an immunohistochemistry assay used in tissue pathology. TuM2-PK, by contrast, was investigated as a marker measured in blood and pleural fluid. They serve different purposes and should not be treated as interchangeable.
BAP1 immunohistochemistry also has limitations: some mesotheliomas retain BAP1 expression, so a retained result does not rule out the disease. No single result should be interpreted apart from the full clinical and pathological picture.
What are the limitations of the new study?
The study included 88 patients at one institution. Although mesothelioma accounted for many of the malignant cases, this was not a large independent validation study of a mesothelioma-specific diagnostic test. Differences in age between the groups also complicate interpretation. Additional research would be needed to establish whether TuM2-PK has a useful role in a narrower setting or in combination with other tests. The present findings do not support it as a standalone diagnostic tool.
What can patients ask if the diagnosis remains uncertain?
Patients may wish to ask whether the diagnosis is supported by a tissue specimen, whether a pathologist experienced in mesothelioma has reviewed the results, and whether more tissue or additional testing could clarify an uncertain finding. They can also ask what imaging shows and whether a second pathology opinion would be helpful.
A negative pleural-fluid result should not automatically be interpreted as proof that mesothelioma has been excluded. The treating medical team must decide whether further investigation is appropriate. Our mesothelioma specialist resource offers additional questions for consultations.
Why this research matters
The search for less invasive diagnostic tests matters: reliable blood or fluid markers could potentially help patients obtain answers sooner or avoid unnecessary procedures. But an insufficiently accurate test can create uncertainty rather than resolve it. The November 18 study illustrates why experimental markers need careful validation before clinicians rely on them. For someone facing a possible mesothelioma diagnosis, the practical priority is understanding what evidence supports the diagnosis—and what remains uncertain.
Original research and medical guidance
- Ali Mazid and colleagues — The Egyptian Journal of Bronchology, November 18, 2026
- National Cancer Institute — Mesothelioma Diagnosis and Prognosis
- British Thoracic Society — Pleural Disease Guideline
Medical information notice: This article summarizes medical research for educational purposes. It does not determine whether any individual has mesothelioma or needs a particular test. Patients should discuss symptoms, imaging, biopsy findings and laboratory results with qualified medical professionals. Humpleby & Strauss, P.C. is a law firm and does not provide medical diagnosis or treatment.